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Abstract 
Objectives 
Homeopathy is a popular treatment modality among patient, however there is sparse research 
about adverse effects of homeopathy. A concept unique for homeopathy, is homeopathic 
aggravation that is understood as a transient worsening of the patients’ symptoms before an 
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expected improvement occurs. From a risk perspective it is vital that a distinction between 
homeopathic aggravations and adverse effects is established. There is a lack of systematic 
information on how frequent adverse effects and homeopathic aggravations are reported in 
studies. Therefore, a systematic review and meta-analysis were performed.  
Design and setting 
Sixteen electronic databases were searched for Randomized Controlled Trials (RCTs). The 
searches were limited from the year 1995 to January 2011. Forty-one RCTs, with a total of 
6.055 participants were included. A subtotal of 39 studies was included in the additional meta-
analysis.  
Results 
A total of 28 trials (68%) reported adverse effects and five trials (12%) reported homeopathic 
aggravations. The meta-analysis (including six subgroup comparisons) demonstrated that no 
significant difference was found between  homeopathy and control with OR 0.99, 95% CI 
0.86 to 1.14, I2 = 54%. More than two third  of the adverse effects were classified as grade 1 
(68%) and two third were classified as grade 2 (25%) and grade 3 (6%) according to the 
Common Terminology Criteria for Adverse Effects. Homeopathic aggravation was classified 
as grade 1 (98%) and grade 3 (2%), suggesting that homeopathic aggravations were reported 
to be less severe than adverse effects. The methodological quality according to a method 
recommended in the Cochrane handbook for RCTs, was high. 
Conclusion 
Adverse effects including the concept of homeopathic aggravations are commonly reported in 
trials. The meta-analysis demonstrated that the proportion of patients experiencing adverse 
effects to be similar for patients randomized to homeopathic treatment compared to patients 
randomized to placebo and conventional medicine.  
 
Introduction 
Homeopathy was established and developed in Germany by Samuel Hahnemann in the late 
18th century, and since then the theory and practice of homeopathy have developed outside the 
established health services. The action of homeopathic remedies is questioned as most 
remedies are diluted to such a high degree that there is only a theoretical probability that 
molecules of the original substance are present in the remedy (1-3). Accordingly, homeopathic 
remedies of high dilutions are pharmacologically inactive. On the other hand some 
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homeopathic remedies are less diluted (D6 or D12), meaning that these remedies could be 
pharmacologically active. However, research suggests (4)  that it is low direct risk connected 
to homeopathic remedies. The possible risk is therefore classified as indirect, related to other 
aspects of clinical context and practice. In medical science, risk can be divided into direct and 
indirect risk. Direct risk is related directly to the intervention itself, such as the medication or 
the homeopathic remedy. Indirect risk is related to the treatment setting, such as the 
practitioner and the caring context (5-7).  
In the United States 2.3% of the adult population used homeopathy in 2007, and 2.9 billion 
USD were spent on homeopathic remedies (8). The 12 month prevalence of those who have 
visited a homeopath in Europe has been found to vary between 2% in Great Britain (9) to 15% 
in Germany (10). A survey among older German adults revealed that 21% used homeopathy for 
their complaints (11). In Scandinavian countries the prevalence of persons who use 
homeopathy fluctuates between 7% and 14% (12).  
Being female, having higher education, suffering from health complaints and using 
conventional health care have all been associated with the use of Complementary and 
Alternative Medicine (CAM), including homeopathy (13-15). Uncontrolled studies of 
homeopathy document consistent and sustained patient satisfaction (15). Patients used 
homeopathy for chronic, physical problems, as well as emotional complaints (14-16). The most 
frequent diagnoses for which they seek homeopathy are allergic rhinitis in adult males, 
headache in adult females and atopic dermatitis in children (17). Homeopathy is one of the 
most common CAM therapies in cancer care in Europe, ranging from 11% across cancer 
diagnoses (18) up to 19% in breast cancer patients (19). Among younger cancer patients in 
Germany, 45% reported that they have used homeopathic remedies during their illness (20). 
The majority of the patients used homeopathy with the aim to increase the body’s ability to 
fight cancer or to improve physical or emotional well-being (19). 
A concept specific to homeopathy is homeopathic aggravations, which is defined as “a 
temporary worsening of existing symptoms following the administration of a correctly chosen 
homeopathic remedy”. This reaction is seen as a favourable response to the treatment and is 
expected to be followed by an improvement (2, 21-23). In 2003, Grabia and Ernst (24) published 
a systematic review to investigate how homeopathic aggravations was reported in RCTs. 
From a total of 25 trials, eight reported homeopathic aggravations and six reported adverse 
effects. The authors claimed that, for safety reasons, the concept should be reported in trials. 
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A systematic review of case reports published in 2012 (25) found that, among the included 38 
primary reports, 30 reported direct adverse effects from homeopathic remedies and eight were 
related to adverse effects caused by the substitution of conventional medicine with 
homeopathy. This review initiated a broad and controversial discussion about the safety of 
homeopathic treatment which has already been raised with regard to the risk of homeopathy 
related to practice by Dantas in 1999 (26). In particular, Tournier et al (27) highlighted the 
importance of differentiation between homeopathic care and clinical negligence. Together 
with poor reporting quality of the primary sources (i.e. of applied potencies of the remedy) 
this may lead to a misinterpretation of causality. Nevertheless this scientific episode 
highlights the need for some criteria or guidelines that enables to document common 
standards of homeopathic treatment. 
So far, homeopathic aggravations have mostly been reported in an anecdotal way. In one case 
(28), a nine-month old baby girl was given several homeopathic remedies to treat atopic 
dermatitis. The child developed Bullous Pemphigoid (BP) during the treatment period and 
when the baby was finally admitted to the hospital, the condition was life threatening. This 
situation occurred because the homeopath misinterpreted the worsening of the symptoms as 
homeopathic aggravations and continued the treatment. In this case only spars information 
regarding the prescription of  the homeopathic remedies was documented and the author 
stated that “no conclusion about the role of the homeopathy in the triggering of BP can be 
made”. However, Posadzki et al. in their review judged Mercury intoxication as a possible 
explanation of the adverse effect as judged by the author of the primary report (25).  
This case illustrates the difficulty of judging the likelihood of homeopathic aggravations and 
adverse effects in homeopathy. Good data on a well-recognized, easily detectable adverse 
effects may be available from randomized clinical studies (RCTs) (29), and since limited 
knowledge of how adverse effects and homeopathic aggravations are reported in trials - A 
systematic review is needed. 
Aims 
The aims of this paper are to 1. Systematically investigate how homeopathic aggravations and 
adverse effects are reported in randomized controlled trials. 2. Classify adverse effects and 
homeopathic aggravations according to the Common Terminology Criteria for Adverse 
Effects (CTCAE) (30). 3. Perform a meta-analysis to evaluate the risk for patients using 
homeopathy (consultation and/or homeopathic remedies) compared to controls.  
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Terminology 
Not only is the homeopathic intervention itself a very complex treatment situation, which 
includes much more components than the remedy, there is, moreover, an astounding variety 
of definitions of harmful events available. This situation makes a thorough discussion of the 
terminology, which forms the basis of the systematic review and meta-analysis presented 
here, necessary.   
The homeopathic intervention is a very elaborate treatment situation that consists of in-depth 
consultations often reaching beyond the topic of bodily complaints and involving 
psychological problems as well. In addition, lifestyle advice is generally included and a part 
of the consultation. 
In terms of safety concerns, the homeopathic remedies themselves are mostly considered 
harmless (4). According to the current pharmacological model any potential harm related to 
remedies of high dilutions must be related to indirect risk (see table 1 for definitions of 
concepts), such as e.g. risk related to the setting effects, such as the practitioner (5, 31). 
According to current scientific knowledge, only remedies of low dilutions have a potential to 
induce direct risk, since they do contain substrate. Nonetheless, homeopathic treatment with  
ultra-molecular remedies has been proven to  be clinically effective, but the mechanisms of 
effect remain unclear and under discussion. It has been speculated, that psychological 
mechanisms such as the placebo effect, potentially play a role (32)  
As a consequence of this complex situation, a rather broad definition of risk, including both 
direct and indirect risk, maybe most appropriate in order to map the potential harm to patients 
related to the homeopathic treatment situation (33). This definition should encompass all 
potentially unwanted effects, without making assumptions about their mechanisms. In the 
light of the obvious shortcomings of the pharmacological model with regard to homeopathy, it 
is moreover, essential, that this definition is also able to cover incidents, that are most likely 
not related to a pharmacological effect.  
In Norway,  the National Norwegian Medicines Agency (34), uses the term adverse effect. In 
this definition, an adverse effect is understood as all diseases or unwanted and/or harmful 
reactions resulting from a medication or an intervention, regardless of their relation to the 
actual treatment. This definition is quite similar to how Edward and Aronson (35), define 
adverse effects, namely as a term that encompasses all unwanted effects. In this understanding 
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of adverse effect, no assumption about mechanism is made and as such, ambiguity is 
minimized.  
According to Edward and Aronson (35), the term adverse effect in the above described 
understanding must be distinguish from the term adverse events. They understand adverse 
event as an adverse outcome that occurs while a patient is taking a drug, thus, there is a strong 
temporal association to the drug, but the harmful event must not necessarily be associated 
with it. Their definition is similar to the definition of adverse events used by the European 
Medicines Agency (36). There, adverse events are defined as “any untoward medical 
occurrence in a patient or clinical trial subject administered a medical product”. But here as 
well, these events do not necessarily have a causal relationship with the treatment. At the 
same time, the European Medicines Agency defines adverse effects as a response to a 
medicinal product which is noxious and unintended (36). In conclusion,  the European 
Medicines Agency as well as the National Norwegian Medicines Agency have a common 
understanding of the term adverse effect. 
To complicate the situation even more, the term adverse reactions is often used instead of 
adverse effects and both are often used interchangeable. However, an adverse effect is 
generally identified as being linked with the drug, whereas an adverse reaction is directly 
linked to the patient (35, 36).  
Thus, even though it seems that there is a common intuitive understanding of what a harmful 
event related to a treatment is, it seems to be challenging to find a common terminology of 
terms to describe and define it. This confusing situation is most illustrative demonstrated by 
the fact, that even the current glossary of the CONSORT statement lacks a clear definition of 
adverse event and that a definition is still pending. http://www.consort-
statement.org/resources/glossary. Several attempts have been made to facilitate the reporting 
of harm related issues and a checklist for such reports has been developed (37). As a 
conclusion, the authors are well aware that the decision of which definition to choose, is to a 
large extend a matter of choice and other choices are well possible and reasonable.  
The National Research Center for Complementary and Alternative Medicine (NAFKAM) in 
Norway is a governmentally funded national agency, organized as part of the  Department of 
Community Medicine at the Arctic University of Norway. One major goal related to the 
implementation of NAFKAM and thus a part of NAFKAMs assignment is to ensure and 
frame the safe use of complementary medicine for the Norwegian citizens. The systematic 
 7 
review presented here is part of this assignment. It seem reasonable that NAFKAM utilizes a 
risk definition, which is in line the National Norwegian Medicines Agency(33),  The Term 
“adverse effect” as it is understood in this definition includes more sources of risk than 
merely those related to the drugs and thus covers a sufficiently broad spectrum of potential 
risks. It is therefore also suitable for the complex treatments situation in complementary 
medicine in general and thus for homeopathy as a special case. Thus, we will use this term 
and understanding of harm for this review, being well aware, that this represents a conscious 
choice, rather than a generally accepted universal definition. 
Moreover, we are aware, that the translation of the risk concept of homeopathic aggravation 
into a conventional medical terminology is challenging and may reflect a compromise, 
nonetheless a definition is needed in order to describe and document the potential risk related 
to homeopathy in all its facets. Homeopathic aggravation is a reaction to homeopathy which 
is a complex treatment regimen. Hence, a concept that includes both direct and indirect risk in 
order to categorize homeopathic aggravation into a conventional term is needed. We have 
therefore chosen to categorize homeopathic aggravation as a special kind of adverse effects in 
this review.  
Hanemann stated in the Organon der Heilkunst  § 161”….. the so-called homeopathic 
aggravation, or rather the primary action of the homeopathic medicine that seems to increase 
somewhat the symptoms of the original disease, to the first or few hours, this  is certainly true 
with respect to diseases of a more acute character and of recent origin: but where medicines of 
long action have to combat a malady of considerable or very long lasting……Such increase of 
the original symptoms of a chronic disease can appear only at the end of treatment when the 
cure is almost quite finished.” Consequently, temporary and short time aggravations may be 
observed and reported in RCTs. However, longer lasting homeopathic aggravations  are rather 
unlikely to be observed in clinical trials. 
As a final caveat, we would like to pay attention to the fact that the only available information 
on adverse effects and homeopathic aggravations for this review was based on the 
information provided by the authors of the included trials.  
Therefore, the results presented here are based on the following definitions: 
• Adverse effects 
• homeopathic aggravations 
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Table 1: Definitions of harm concepts 
Table 1: Definitions of harm concepts  
Terminology Definition References 
Risk A compound measure of the probability of an event, and 
the magnitude and impact of its potentially negative 
outcome of that event. 
(38),(35) 
Indirect risk Risk related to the setting effects, such as the practitioner 
rather than to the medicine. For example, a practitioner with 
limited medical and homeopathic skills may overlook 
serious symptoms and thereby cause a delay in necessary 
conventional treatment. 
(6), (33) 
Direct risk Risk related to the intervention, e.g., harm caused by 





(direct and indirect 
risk) 
A temporary worsening of existing symptoms following the 
administration of a correctly chosen homeopathic 




(direct and indirect 
risk) 
All diseases or unwanted and/or harmful reactions resulting 
from a medication or an intervention, regardless of their 
relation to the actual treatment. 
(34),(35) 
Adverse reactions 
(direct and indirect 
risk) 
Present when the right drug was administered for the 
correct indication, in the proper dose, by the right route, yet 
still the patient develops an unwanted symptom, suffers 
unexpectedly, and is exposed to unpreventable harm. 
Adverse reactions may also result from some diagnostic 





An appreciably harmful or unpleasant reaction, resulting 
from an intervention related to the use of a medicinal 
product. The reaction predicts hazards regarding future 
administration and warrant prevention or specific treatment, 






The focus question was: 
Is homeopathy associated with adverse effects and/or homeopathic aggravations? 
The PICO format was used when searching for relevant articles, which included the following 
four parts: 
Population: Patients using homeopathy, physicians and homeopaths who reported adverse 
effects and homeopathic aggravations in the included studies 
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Intervention: Homeopathy, including everything a homeopath does in the consultation, such 
as a diagnostic in-depth interview, prescription of remedies, and life-style 
advice  
Comparison: Placebo, conventional medicine, usual care, waiting lists, other complementary 
and alternative treatments (including herbs) 
Outcome: Adverse effects, adverse events, adverse reactions, tolerability, side effects (or 
other safety terminology) and homeopathic aggravations  
The following electronic databases were searched: AMED, Cinahl, Cochrane Central Register 
for Controlled Trial (Central) in the Cochrane library, Embase, Medline, PsycINFO, PubMed, 
Datadiwan, GIRI, HomBRex, Hom-Inform, CAM Quest, CAMbase, Theme eJournals and 
Karger. A manual search was performed in complementary medicine journals, collections of 
publications from experts in homeopathy and homeopathic philosophy books. In order to find 
additional studies not found by electronic or manual searches, the reference lists of 
publications were also checked. 
Search Methods: Depending on the database, various combinations of MESH terms and 
keywords were used. These MESH terms were used: Homeopathy/Materia Medica/Risk 
Management/Drug tolerance. These keywords were used: 
Homeopathy/homoeopathy/homeopathic/homoeopathic side effect*, safety, adverse effect*, 
adverse events*, homeopathic aggravation*. The filters were clinical trials, RCTs, high 
specificity, any human conditions of humans, English and German. As the meta-analysis by 
Linde et al (41) included studies up to 1995, the searches were limited to the time period from 
January 1992 to January 2011.  
The first author, T.S, performed the searches, read the articles, and extracted the data, while 
T.A. was consulted in cases of doubt. [The Cochrane Library (searches from 2002-2011) and 
the PubMed (searches from 2002-1992) search strings are attached in the appendix].  
The inclusion comprised randomized, therapeutic trials that were double blinded. The trials 
excluded had no registration of homeopathic aggravations or adverse effects. Moreover, all 
drug proving trials, homeopathic pathogenic trials and duplicated publications were excluded. 
Methodological assessment of the included RCTs 
In this present study, the methodological quality of the RCTs was assessed using the criteria 
in the Cochrane Reviewers’ Handbook (42). The following criteria were included in the 
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assessment: Participants, dropouts, power calculation, intention-to-treat analysis, method 
(allocation concealment and blinding), intervention, duration of treatment, main finding, and 
funding (table 2). The trials were rated as follows: 
A was used to indicate an RCT with a high level of quality in which all the criteria were met. 
Adequate measures to conceal allocation were made. The central randomization was either 
serial numbered, opaque, sealed envelopes or other descriptions that contained convincing 
elements of concealment. Hence, low risk of bias. 
B was used when the authors did not report allocation concealment at all, or reported an 
approach that did not fit one of the categories in A. Hence, moderate risk of bias. 
C was used when the method of allocation was not concealed, such as alternation methods or 
the use of case record numbers. Such trials were excluded because of high risk of bias. 
Total number and classification of adverse effects and homeopathic aggravations 
Studies were extracted for data on adverse effects and homeopathic aggravations according to 
the following criteria: The total number of adverse effects, number of patients experiencing 
adverse effects, the total number of homeopathic aggravations and the total number of 
patients experiencing aggravations, and the CTCAE grading of the symptoms. When 
summarizing the data, the total number of adverse effects and homeopathic aggravations were 
counted, regardless of the number of participants who experienced them. This means that one 
patient may experience more than one adverse effect. Adverse effects and homeopathic 
aggravations were recorded as reported and stated in the included trials. This means that the 
CTCAE grading  was entirely dependent on the information provided in the articles.   
In order to evaluate the harmful events according to severity, the CTCAE grading system was 
chosen (30).The CTCAE system grades adverse effects from 1 to 5, where 1 is mild, 2 is 
moderate, 3 is severe or medically significant, 4 is life threatening, and 5 is lethal. When 
reporting the grading of adverse effects, we reported the harmful events without the number 
of patients experiencing the events. 
The CTCAE grading system was also applied for homeopathic aggravations. The reason was 
that the grading system relates to new or worsening symptoms, which means that the cause of 
the new or worsening symptoms is irrelevant for the grading. Three researchers (TA, AK, TS) 
categorized and graded the data. When disagreements occurred, the events were discussed until 
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consensus was reached.  TS is a certified homeopath and acupuncturist, and the TA is a certified 
acupuncturist in Norway. 
Meta- analyses 
For the calculation of the meta-analysis, the study populations were divided in patients 
experiencing adverse effects vs. patients not experiencing adverse effects in both homeopathy 
and control groups. If the studies were homogenous regarding the study design, participants, 
interventions, control and outcome measures, they were combined in a meta-analysis. 
Heterogeneity was defined as being significant, if P < 0.10.  
Based on the total number of participants randomized to the treatment or control group, odds 
ratios and 95% confidence intervals were calculated from the number of patients who 
experienced adverse effects in each group. In 15 studies with no adverse effects in one or both 
groups, a continuity correction of 0.5 was added to arrive at a valid approximation of an odds 
ratio according to the current recommendations on analysing adverse effect data (43). To 
perform a meta-analysis, data were entered directly from the data sheets into Review Manager 
5 computer program (44).  
Results 
Outcome of the literature searches  
A total of 1,129 articles with RCTs were identified. They were initially examined on the basis 
of titles and abstracts, and 1,079 were excluded from further examination for the following 
reasons: Seventy-five articles did not record adverse effects or homeopathic aggravations, 44 
described homeopathic proving trials, 324 were irrelevant (according to the criteria), 439 were 
multiple article registrations in databases, 62 were written in other languages than English and 
German and 135 were CAM studies other than homeopathy. Seven articles were included 
after searching German databases. After a closer examination of the 57 identified studies (45-
47) (48-51) (52-102), 16 were excluded (table 1) (46-48, 89-102). A total of 41 RCTs (48-88) with 6,055 
subjects were included in this review.  
Figure1. Flow chart of the randomized controlled trials 
The control intervention was a placebo in most of the RCTs (n=31) (48-51, 53, 55-57, 60-71, 73, 74, 
76, 78-83, 87, 88, 103). Further, placebo and conventional medicine in one trial (n=1) (86), herbal 
medicine (Gingo biloba) in one trial (n=1) (59), usual care in one trial (n=1) (72) and 
conventional medicine in five trials (n=5) (75, 82, 84, 85, 87). Any human condition of humans 
and any homeopathic remedy were considered.    
 12 
Table 2: Excluded studies 
Methodological quality of the RCTs  
A total of 32 trials (78%) were rated as A, demonstrating that the methodological quality in 
these trials was of high quality with low risk of bias. Nine trials (22%) were rated as B (48, 50, 
53, 59, 64, 67, 69, 73, 75), demonstrating average quality and medium risk of bias. A total of 22 
trials (54%) reported both sample size calculations and intention to treat analyses. Eight trials 
(20%) did not report sample size calculations or intention to treat analyses (53, 57, 60, 61, 64, 67, 68, 
73). Four of these studies also had a methodological quality of B (medium quality) (53, 64, 67, 73). 
Based on this evaluation we concluded that the methodological quality of the majority of 
these trials was high. Key data of these studies are summarized in table 3. The column 
Participants refers to the number of participants randomized to either the treatment or control 
group. Dropout refers to participants in the treatment and control group who left the study. 
Therefore, participants who completed the study can be calculated as follows, e.g., Aabel 
2000: (n=37) – (n=3) = (n=34) in the treatment group and (n=33) – (n=1) = (n=32) in the 
control group.  
Table 3: Assessment of the methodological quality of the randomized controlled trials 
Adverse effects 
From a total of 41 RCTs, 28 trials (68%) reported adverse effects. A total of 491 participants 
experienced 690 adverse effects, 426 in the treatment groups and 264 in the control groups. 
Twelve trials (29%) reported no cases of adverse effects. The adverse effects were mostly 
categorized as gastro-intestinal disorders, headache/dizziness or dermatitis. Sixty-eight 
percent (n=466) were characterized as CTCAE grades 1, 25% as grade 2 (n=174), 6 % as 
grade 3 (n=39), 0,4 % as grade 4 (n=3) and 0,2 % as grade 5 (n=2).The adverse effects 
categorized as grade 4 and 5 were not related to study medication. Key data of adverse effects 
are summarized in table 4. 
The adverse effects were patients or physician reported and the harmful events were causality 
assessed in three trials (55, 56, 70). There was an inconsistent use of referring measures of 
adverse effects. Twenty-seven trials (54-56, 59, 61, 62, 64, 65, 70-73, 75-78, 80-86, 88, 91) used the 
terminology adverse effects or adverse events. These trials assessed the symptoms as 
mild/moderate or severe, or serious or non-serious. A three or four point tolerability scale was 
used in six trials (49, 50, 59, 84, 85, 88). Adverse effects were descriptively reported in five trials 
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(49, 51, 60, 78, 79). Four trials used the term adverse drug reactions (66-68, 75), two trials applied 
side effects (63, 69), and one trial used unexpected effects (58). 
Homeopathic aggravations  
Five RCTs (12%) (54, 65, 79, 80, 86) reported homeopathic aggravations four of these also 
reported adverse effects. One hundred and seven participants experienced a total of 158 
homeopathic aggravations, 91 in the treatment groups and 67 in the control groups. The 
remaining 36 RCTs (88%) reported no cases of homeopathic aggravations. Homeopathic 
aggravations were patient and physician reported, and the studies did not report whether the 
patients had been informed about the possibility of experience such events.  Homeopathic 
aggravations were reported as worsening of the patients’ symptoms, such as exacerbation of 
allergy, asthma, eczema, headache and hot flushes. Ninety-eight present was classified as 
CTCAE grade1 (n=171) and 2% was classified as grade 3 (n=4) (severe asthma attacks). Non- 
events were classified as grade 2, 4, and 5. 
Two trials classified homeopathic aggravations as adverse effects (80, 86). One study (52) 
reported these data descriptively, another study (11) classified them as adverse reactions, and 
one trial(104) classified worsening of symptoms as homeopathic aggravations. Both complex 
and single remedies of low and high dilutions were associated with reported adverse effects or 
homeopathic aggravations. Key data of homeopathic aggravations are summarized in table 4.  
Table 4:  and 
Meta-Analyses 
Adverse effects data from 39 RCTs were included in the meta-analysis with a total of 5.902 
subjects (figure 2).  
1. Homeopathy versus overall control 
An overall comparison was made between homeopathy and control. Thirty-nine trials (5.902 
participants) made this comparison and no significant difference was found between  
homeopathy and control (426/2947 versus 264/2955), with OR 0.99, 95% CI 0.86 to 1.14, I2 = 
54%.  
Different subgroup meta-analyses according to the categories of controls were performed and 
presented below. 
2. Homeopathy versus placebo 
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A comparison was made between homeopathy and placebo. Thirty-one trials (4.836 
participants) made this comparison and no significant difference was found between 
homeopathy and placebo (n= 220/2436 versus n=157/2400), with OR 1. 03, 95% CI 0.89 to 
1.20, I2 = 49%.  
3. Homeopathy versus conventional medicine 
There was no significant difference between homeopathy and conventional medicine in a 
meta-analysis of five trials (43/355 versus 71/401), with OR 0.82, 95% CI 0.56 to 0.1.21, I2 = 
67%.  
4. Homeopathy versus herbs 
A comparison was made between homeopathy and herbal medicine. One trial (170 
participants) made this comparison, and no significant difference was found between the 
groups (OR 0.72, 95% CI 0.25 to 2.07, P = 0.54).  
5. Homeopathy versus usual care 
A comparison was made between homeopathy and usual care. One trial (47 participants) 
made this comparison and reported the same number of adverse effects in  the homeopathy as 
in the usual care group (1//23 versus 1/24), with OR 1.02, 95% CI 0.30 to 3.51, P = 0.97. 
6. Homeopathy versus conventional medicine and placebo 
There was no significant difference between homeopathy and conventional medicine and 
placebo in a meta-analysis of one trial  (7/46 versus 5/47), with OR 1.20, 95% CI 0.71 to 2.03, 
P = 0.50.  
One study, in which the numbers of adverse effects without stating the respective number of 
patients affected by the adverse effects, was excluded from the analyses (105). Another study 
(52), that reported only homeopathic aggravation was also excluded from the meta-analysis. 
Figure 2: Forest plot for the randomized controlled trials, including sub-group analysis 
according to the category of controls. 
In order to investigate whether there was a difference between studies of  low and high 
potency homeopathy, we performed a One Way Anova test. We found that the mean number 
 15 
of adverse effects  in studies (n=20) with low potency (D4 toD30) was 8.5%, compared to 
15.5% in studies (n=6) with high potency ( D200 and higher) (p=0.181).  
Discussion 
In this present review we found that adverse effects were reported in 68% of the RCTs, More 
than two third of these events was classified as CTCAE grade 1 (minor) and one third as 
grade 2 and 3 (moderate and severe/significant). The meta-analysis demonstrated the 
proportion of patients experiencing adverse effects to be similar for patients randomized to 
homeopathic treatment compared to patients randomized to control such as placebo and 
conventional medicine. 
The CTCAE grading of adverse effects and homeopathic aggravations was solely based on 
the information provided in the articles. This grading must, therefore, be interpreted with 
caution. As such, the grading applied here should be understood as merely an approximation 
to a CTCAE grading.  
Studies of effect require as a general rule randomized controlled trials. Adverse effects, 
however, may also be effectively investigated in non-randomized studies (106). Papanikolaou 
(107) compared the risks of 13 major harms due to medical interventions using data from both 
randomized controlled trials and observational studies. The results suggested that, if a 
nonrandomized study finds harm, changes are that a randomized study would find even 
greater harm in terms of the magnitude of absolute risk. The authors concluded that contrary 
to current belief, non-randomized studies were often more conservative in their estimates of 
risk compared to randomized trials.  Moreover, rare adverse effects or long-term adverse 
effects are rather unlikely to be observed in clinical trials, and a thorough investigation may 
require the inclusion of cohort studies (42). Our study team have therefore in addition to the 
study presented here, also conducted a systematic review and meta-analysis of observational 
studies that will be published later. 
A limiting factor in all meta-analyses is heterogeneity of included studies. Being aware that 
heterogeneity might be underestimated in a fixed effect model, and the current discussion on 
applying fixed or random effect models in meta-analyses of binary adverse data (108), we 
decided to perform a simple random effect model. This model is also recommended in meta-
analysis of rare binary adverse effect data (43). According to the argumentation of Friedrich et 
al. (109) we decided to include studies with zero-cell counts because the exclusion of such trials 
enhances the "risk of inflating the magnitude of the pooled treatment effect". By using a 
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continuity correction of 0.5 for studies with zero-cell counts, odds ratio can still be estimated 
and summed up with standard meta-analysis methods. The inclusion of zero event studies is 
particularly important in cases of adverse effects as applying the standard continuity 
correction leads to a conservative, but error free, approximation of the risk of adverse effects 
(108). Moreover, the sample sizes of such trials contribute to the total effect size and make this 
more valid. On the other hand, this present review investigating adverse effects,  so whether 
the pattern of adverse effects are homogeneous across studies should be of no concern, given 
they were for different conditions and involving different treatments, one would expect 
heterogeneity. 
The studies using high potency homeopathy had twice as many adverse effects reported than 
studies using low potency, however not at a significant level. We believe that this result is   
due to low number of studies included in the analysis. The reason was that the name and 
potency of the homeopathic remedies administrated to study participants were not reported in 
several trials  (e.g. individualized homeopathy). 
To address the question about publication bias we did a funnel plot. This demonstrated the 
absence of publication bias in this systematic review, hence not shown in this present paper. 
However, the topic in this review was not treatment effect, but the frequency of adverse 
effects in the included trials.  
Strong efforts have been made to retrieve all RCTs on the subject, but one cannot be 
absolutely certain that they have all been found. On the other hand, the additional searches in 
German databases, a country with a strong homeopathic research tradition, strengthen the 
possibility that the majority of the available studies have been included. This methodological 
approach may have minimized the possibility for selection bias in this systematic review.  
A total of 62 (n=62) studies were excluded because they were in other languages, mainly 
Russian and French. Many researchers find that data from more than 40 studies in a 
systematic review may be difficult to handle and therefore not recommended (110). We believe 
that the studies excluded from this review should be included in a separate review. 
An inconsistent use of safety terminology was found in the included trials. Harm data was 
reported by different concepts, such as adverse effects, adverse events, side effects and 
adverse drug reactions. The grading was measured on different scales (mild, moderate and 
severe or serious vs. non-serious). Moreover, homeopathic aggravations were classified as 
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adverse effects and adverse reactions. This inconsistent use of terminology made it difficult to 
categorize and evaluate the data systematically. Hence, a consistent taxonomy is preferable 
and in line with WHO recommendations (111).   
The adverse effects in this present review were found to be minor to moderate and transient 
events, which is in line with Dantas and Rampes (4). Grabia and Ernst (24) found in a 
systematic review of homeopathic aggravations in 25 placebo-controlled RCTs, 33 adverse 
effects in the placebo groups and 97 in the homeopathy groups. No grading of the adverse 
effects was given in the article.  
It is possible that adverse effects have been under-reported. Many patients and homeopaths 
find it difficult to accept that homeopathy can cause adverse effects, since the treatment is 
“natural “and thereby considered to be safe. Moreover, many homeopaths believe that high 
diluted remedies does not cause adverse effects (112). 
Grabia and Ernst (24) reported also that 40 cases of aggravation in the placebo groups and 63 
cases in the homeopathy groups. The authors concluded that although the included RCTs 
mentioned the phenomenon of homeopathic aggravations, the evidence was not strong enough 
to provide support for the existence of aggravations. The frequency of homeopathic 
aggravations reported in the review from Grabia and Ernst, is in accordance with the findings 
from this present review. However, the frequency of reported homeopathic aggravations may 
be too low, since there is a lack of an adequate reporting system that include homeopathic 
aggravations. 
Conclusion 
Adverse effects including the concept of homeopathic aggravations are commonly reported in 
trials. The meta-analysis demonstrated that the proportion of patients experiencing adverse 
effects to be similar for patients randomized to homeopathic treatment compared to patients 
randomized to placebo and conventional medicine. The different harm terminology applied in 
the included studies and lack of standard reporting procedures made this work challenging 
and may bias this findings. 
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Figure 2: Forest plot for the randomized controlled trials, including sub-group analysis 
according to the category of controls 
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Table 1: Definitions of concepts 
Table 1: Definitions of harm concepts  
 
Terminology Definition References 
Risk A compound measure of the probability of an event, and 
the magnitude and impact of its potentially negative 
outcome of that event. 
(36),(32) 
Indirect risk Risk related to the setting effects, such as the practitioner 
rather than to the medicine. For example, a practitioner with 
limited medical and homeopathic skills may overlook 
serious symptoms and thereby cause a delay in necessary 
conventional treatment. 
(6), (37) 
Direct risk Risk related to the intervention, e.g., harm caused by 





(direct and indirect 
risk) 
A temporary worsening of existing symptoms following the 
administration of a correctly chosen homeopathic 




(direct and indirect 
risk) 
All diseases or unwanted and/or harmful reactions resulting 
from a medication or an intervention, regardless of their 
relation to the actual treatment. 
(39),(32) 
Adverse reactions 
(direct and indirect 
risk) 
Present when the right drug was administered for the 
correct indication, in the proper dose, by the right route, yet 
still the patient develops an unwanted symptom, suffers 
unexpectedly, and is exposed to unpreventable harm. 
Adverse reactions may also result from some diagnostic 





An appreciably harmful or unpleasant reaction, resulting 
from an intervention related to the use of a medicinal 
product. The reaction predicts hazards regarding future 
administration and warrant prevention or specific treatment, 

















Table 2: Excluded studies 
Table 2: Excluded studies 
Study id Method Reason for exclusion 
Aabel, 2010 RCT On a general level, discussed whether a prophylactic treatment 
schedule could minimize the problems of HA in homeopathy. No 
AE/HA data 
Bell, 2004 RCT No AE/HA data 
Bell, 2004 RCT No AE/HA data 
Active medication was a herbal ointment Bernstein, 2006 RCT 
Ferrera , 2008 RCT Active medication was not homeopathic medication 
Frass, 2011 RCT Double publication 
Friese 1997 RCT Double publication (Friese 2001) 
Garrett, 1997 RCT Unclear randomization process 
Hill, 1996 RCT Active medication was a herbal product (mother tincture) 
Jeaner, 2000 RCT Data on “secondary effects”, which was not defined 
Katz, 2005 RCT No results available, due to low compliance 
Mousavi, 2009 RCT Suggested that the verum (Ignatia) was a potentially low risk 
option in treating lichten planus, without reporting AE/ HA 
Schirmer, 2000 RCT Not a homeopathic intervention. Reinjection of patient´s own 
blood ("Eigenblut") 
Seeley, 2006 RCT The study reported no  complications after face lifts, no AE/HA 
data from homeopathic treatment  
Strösser, 2000 RCT No AE/HA data 
Tveiten, 2003 RCT Pooled data from two studies 
AE: Adverse effects 
HA: Homeopathic aggravations 
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